Abstract:To improve the outcomes of research and medicine, government-based international research funding agencies have implemented various types of policies and mechanisms with respect to sex as a biological variable and gender as a sociocultural factor. After the 1990s, the US National Institutes of Health (NIH), the Canadian Institutes of Health Research (CIHR), and the European Commission (EC) began requesting that applicants address sex and gender considerations in grant proposals, and offering resources to help the scientific community integrate sex and gender into biomedical research. Although it is too early to analyze data on the success of all of the policies and mechanisms implemented, here we review the use both of carrots (incentives) and sticks (requirements) developed to motivate researchers and the entire scientific research enterprise to consider sex and gender influences on health and in science. The NIH focused on sex as a biological variable (SABV) aligned with an initiative to enhance reproducibility through rigor and transparency; CIHR instituted a sex- and gender-based analysis (SGBA) policy; and the EC required the integration of the "gender dimension," which incorporates sex, gender, and intersectional analysis into research and innovation. Other global efforts are briefly summarized. Although we are still learning what works, we share lessons learned to improve the integration of sex and gender considerations into research. In conjunction with refining and expanding the policies of funding agencies and mechanisms, private funders/philanthropic groups, editors of peer-reviewed journals, academic institutions, professional organizations, ethics boards, health care systems, and industry also need to make concerted efforts to integrate sex and gender into research, and we all must bridge across silos to promote systemwide solutions throughout the biomedical enterprise. For example, policies that encourage researchers to disaggregate data by sex and gender, the development of tools to better measure gender effects, or policies similar to SABV and/or SGBA adopted by private funders would accelerate progress. Uptake, accountability for, and a critical appraisal of sex and gender throughout the biomedical enterprise will be crucial to achieving the goal of relevant, reproducible, replicable, and responsible science that will lead to better evidence-based, personalized care for all, but especially for women.

Sex as a biological variable for cardiovascular physiology

Sex as a Biological Variable in Emergency Medicine Research and Clinical Practice: A Brief Narrative Review

Sex as a Biological Variable in Tissue Engineering and Regenerative Medicine

Guidelines on the Use of Sex and Gender in Cardiovascular Research

Revisiting sex as a biological variable in hypertension research

Sex-Related Effects on Cardiac Development and Disease

Gender-based research underscores sex differences in biological processes, clinical disorders and pharmacological interventions

Review of the Influences of Sex Differences on Health and Disease: What Is the Role of Journals?

Sex-specific considerations in cardiovascular drug therapy

Consideration of sex as a biological variable in diabetes research across twenty years

Sex as a Biological Variable in Atherosclerosis

Sex as a Biological Variable in Oral Diseases: Evidence and Future Prospects

The Influence of Sex on Cardiac Physiology and Cardiovascular Diseases

Cardiovascular sex-differences: insights via physiology-based modeling and potential for noninvasive sensing via ballistocardiography

Gender-specific genetic and epigenetic signatures in cardiovascular disease

Editorial: Sex Differences and Cardiovascular Therapeutics

Sex Differences in Molecular Mechanisms of Cardiovascular Aging

Sex differences in metabolism and cardiometabolic disorders

Evaluating sex as a biological variable in preclinical research: the devil in the details

The Integration of Sex and Gender Considerations Into Biomedical Research: Lessons From International Funding Agencies

A gender perspective on diet, microbiome, and sex hormone interplay in cardiovascular disease